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a b s t r a c t
Antimicrobial-resistant Escherichia coli are a concern for military health services. We studied 100 extendedspectrum beta-lactamase (ESBL)-producing and non-producing E. coli clinical and surveillance isolates from military personnel and civilians at Brooke Army Medical Center (2007–2011). Major E. coli lineages, most prominently ST10 (24%), ST131 (16%), and ST648 (8%), were distributed much as reported for other North American
populations. ST131, represented mainly by its resistance-associated ST131-H30 clonal subset, was uniquely associated with a clinical origin, regardless of ESBL status. Thus, clonal background predicted resistance phenotype
and clinical versus surveillance origin, and these ﬁndings could assist military clinicians and epidemiologists.
Published by Elsevier Inc.

1. Introduction
Extraintestinal pathogenic Escherichia coli (ExPEC) cause most community and hospital-associated extraintestinal E. coli infections (Johnson and
Russo, 2005). Speciﬁc ExPEC lineages, or sequence types (STs), are commonly multidrug-resistant (MDR), and have been associated with international
travel and medical care. The acquisition of difﬁcult-to-treat, antimicrobialresistant ExPEC is therefore a concern for military health services.
In this study, we examined the distribution of E. coli genotypes identiﬁed among clinical and surveillance (e.g. skin colonization) isolates
from deployed and non-deployed active duty US military personnel
and civilians, collected as part of routine medical care at a USmilitary
medical center. Stool surveillance isolates were not included in this
study. We sought to determine whether military personnel (especially
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those with a history of international deployment or injury), when infected or colonized cutaneously with E. coli, were at an increased risk
of having speciﬁc extensively drug-resistant major lineages of ExPEC.
In addition, we attempted to deﬁne the characteristics of these lineages
as they occur among military personnel. We focused speciﬁcally on the
presence of sequence type 131 (ST131) and its resistance-associated
H30 and H30Rx subclones within this population, and compared these
strains” prevalence with data collected from veterans receiving care
within the Veterans Health Administration in 2011 (Colpan et al., 2013).
2. Materials and methods
2.1. Isolates and subjects
The study isolates included 100 de-identiﬁed archival E. coli clinical and
surveillance isolates, which were obtained along with associated information
(specimen type, collection date, collection site, isolate source, injury during
deployment, etc.) from the Molecular Biology Laboratory at Brooke Army
Medical Center, JBSA Fort Sam Houston, TX. The isolates had been recovered
This document is a U.S. government work and
is not subject to copyright in the United States.
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Table 1
Extraintestinal pathogenic Escherichia coli source and characteristics.
Prevalence of trait, No. of isolates (%)
Clinical

Surveillance

Host characteristic,
phylogroup, or STa

Total
(n = 100)

ESBL-producing
(n = 25)

Non-ESBL-producing
(n = 25)

ESBL-producing
(n = 25)

Non-ESBL-producing
(n = 25)

P valueb

Active duty
Deployment injury
Group A
Group B1
Group B2
Group C
Group D
Group F
ST10 (group A)
ST131 (group B2)
ST131 H30
ST131 H30Rx
ST131 non-H30
ST648 (group F)

84 (84)
65 (65)
30 (30)
13 (13)
31 (31)
2 (2)
16 (16)
8 (8)
24 (24)
16 (16)
14 (14)
8 (8)
2 (2)
8 (8)

18 (72)
11 (44)
8 (32)
2 (8)
8 (32)
1 (4)
5 (20)
1 (4)
8 (32)
8 (32)
6 (24)
4 (16)
2 (8)
1 (4)

20 (80)
1 (4)
4 (16)
3 (12)
14 (56)
1 (4)
1 (4)
2 (8)
1 (4)
6 (24)
6 (24)
3 (12)
0 (0)
2 (8)

22 (88)
19 (76)
10 (40)
3 (12)
2 (8)
0 (0)
5 (20)
5 (20)
7 (28)
1 (4)
1 (4)
0 (0)
0 (0)
5 (20)

24 (96)
18 (72)
8 (32)
5 (20)
7 (28)
0 (0)
5 (20)
0 (0)
8 (32)
1 (4)
1 (4)
1 (4)
0 (0)
0 (0)

0.11
b0.001
0.31
0.73
0.003
n.a.c
0.26
0.08
0.06
0.01
0.60
n.a.c
n.a.c
n.a.c

a
ST = sequence type. Only the three most prevalent STs are shown. Other STs that accounted for ≥3% of isolates each, in order of descending overall prevalence (no. of isolates), included: ST38 (5%), ST95 (5%), ST69 (4%), ST405 (4%), and ST73 (3%).
b
By Fisher's exact test (two-tailed), for four-group comparisons.
c
n.a., not applicable (number too small for statistical analysis).

between 2007 and 2011 from 100 unique military personnel and civilians attending the same military medical center (Table 1) and had been tested for
extended-spectrum beta-lactamase (ESBL) production, as described below.
The archival collections included isolates from patients with a suspected infection (clinical) or who were being screened for antimicrobial-resistant
E. coli from nares or groin skin sites (surveillance). The 100 study isolates
were selected randomly as four groups of 25 isolates each: (i) ESBLproducing clinical isolates, (ii) non-ESBL-producing clinical isolates, (iii)
ESBL-producing surveillance isolates, and (iv) non-ESBL-producing surveillance isolates (Table 1). Specimen type and the subject’s military versus civilian status and deployment history did not inﬂuence isolate selection.
The study was approved by research oversight committees at the
participating institutions. It did not qualify for review by the respective
institutional review boards due to its use of archived isolates that had
been collected for routine monitoring purposes, along with generic
deidentiﬁed epidemiological data.
2.2. Laboratory analysis
Antimicrobial susceptibilities and ESBL production was determined
using the BD Phoenix Automated Microbiology System (Becton Dickinson
and Company, Sparks, MD, USA) per manufacturer guidelines utilizing
NMIC/ID-123 panels. Minimum inhibitory concentration (MIC) results
were interpreted according to the Clinical Laboratory and Standards Institute criteria (Clinical and Laboratory Standards Institute, 2013). In addition, isolates were assessed molecularly for blaCTX-M-15, major E. coli
phylogenetic group (phylogroup) (Clermont et al., 2013), ST or ST complex (STc; as determined by fumC-ﬁmH typing (Weissman et al., 2012),
full or partial MLST (Maiden et al., 1998), or STc-speciﬁc PCR assays
(Clermont et al., 2014; Johnson et al., 2009; Matsumura et al., 2012)),
membership in the ST131-H30 clonal subset or its sublineage ST131H30Rx (Banerjee et al., 2013), O type (O16 and O25b only) (Johnson
et al., 2014), and extended virulence genotype (for 50 markers)
(Johnson et al., 2015). Resistance scores were deﬁned as the number of
antibiotic classes to which an isolate exhibited resistance. Virulence scores
were deﬁned based on the raw count of detected virulence genes.
2.3. Statistical analysis
Comparisons of proportions were tested using Fisher's exact or chisquared tests. Comparisons of scores were tested using the Wilcoxon
rank-sum test.

3. Results
3.1. Clinical and epidemiological data
The 100 source subjects included 84 (84%) active duty military personnel and 16 (16%) civilians receiving care at Brooke Army Medical
Center (Table 1). Of 65 subjects with a known injury, 49 (75%) were injured during military deployment, which occurred exclusively in Iraq
and/or Afghanistan. E. coli isolates recovered from these 49 deployed
and injured military members included 10 isolates from wound sites,
2 from blood and 37 collected from the groin area, as part of surveillance
sampling. The 50 clinical isolates were from urine (n = 18), blood (n =
8), wound (n = 23), and body ﬂuid (n = 1). The 50 surveillance isolates
were from groin (n = 49) and nares (n = 1).
3.2. Phylogroups
The 4 most common E. coli phylogroups overall, in descending frequency, were B2 (31%), A (30%), D (16%), and B1 (13%) (Table 1).
Phylogroup B2 isolates were uniquely over-represented among the clinical isolates. Phylogroup A isolates (speciﬁcally ST10), although somewhat more common among surveillance than clinical isolates, were
more common among clinical isolates than expected based on prior
work (Salipante et al., 2015).
3.3. Sequence Types
The 8 most common STs, in descending frequency, were ST10 (24%),
ST131 (16%), ST648 (8%), ST38 (5%), ST95 (5%), ST69 (4%), ST405 (4%),
and ST73 (3%). Collectively, these 8 predominant STs accounted for 69%
of the population. No temporal prevalence trends were apparent for any
speciﬁc STs (not shown).
Statistical comparisons were done only with the 3 most common
STs. ST10 was under-represented among non-ESBL-producing clinical
isolates, whereas ST648 was over-represented among ESBL-producing
surveillance isolates and absent among non-ESBL surveillance isolates.
The combined prevalence of the three most common STs (ST10, 131,
and 648) varied by host group, i.e., 36/84 (43%) for active duty subjects
(including 24/49 [49%] for subjects with deployment-related wounds),
versus 12/16 (75%) for civilian subjects (p = 0.02).
ST131, the most prevalent ST among clinical isolates, was the only ST
that was signiﬁcantly over-represented among clinical isolates as
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compared with surveillance isolates, regardless of ESBL status (Table 1).
Fourteen (88%) of the 16 ST131 isolates belonged to the H30 subclone,
with 8 (50%) of the H30 isolates belonging to the H30Rx sublineage.
All ST131 isolates were O25b-positive except for one, which was nonH30 and O16-positive. ST131, H30, and H30Rx isolates were similarly
prevalent among clinical isolates from active duty personnel versus civilians, and from subjects with deployment-related injuries versus
other sources (not shown).
3.4. blaCTX-M-15
Overall, 31 (62%) of the 50 ESBL-producing isolates contained blaCTX-M-15,
which was similarly prevalent among clinical and surveillance isolates
(14/25 [56%] versus 17/25 [68%]: p = 0.38). blaCTX-M-15 was not associated with active duty status or deployment injury (not shown). ST131
accounted for 7 (14%) ESBL-producing and 5 (16%) blaCTX-M-15carrying isolates, with the majority of these belonging to the H30Rx
ST131 subclone. In contrast, ST10 accounted for 15 (30%) ESBLproducing and 12 (39%) blaCTX-M-15-carrying isolates.
3.5. Virulence Scores
Overall, virulence scores were higher among non-ESBL-producers
than ESBL-producers (median, 8.5 versus 6, respectively; P = 0.02), regardless of clinical versus surveillance source. In contrast, they were
similar among isolates from active duty personnel (median 7, range
1–24), including those with deployment-related injuries (median 7,
range 1–22), and civilians (median 6.5, range 2–24).
Median virulence scores varied greatly between the 3 most common
STs, with ST131 highest (11, range 6–15), ST648 intermediate (7.5,
range 6–11), and ST10 lowest (4, range 2–12). They also varied greatly
by phylogroup, with group B2 highest (12, range 6–24), groups D (8,
range 4–16) and F (7.5, range 6–11) intermediate, and groups A (4,
range 2–12) and B1 (2, range 1–8) lowest.

3.6. Antimicrobial resistance
The proportions of isolates exhibiting resistance to speciﬁc antimicrobial agents and classes varied signiﬁcantly by study group
(Table 2). Whether assessed by prevalence or resistance scores, resistance to the studied antimicrobial agents was associated closely with
ESBL status, but minimally with clinical versus surveillance source. All
but one of the isolates with a resistance score ≥6 (n = 39) was ESBLpositive. Resistance scores were slightly higher among isolates from civilians (median, 5.5) versus active duty personnel (median, 5.0) (P =
0.09). Among clinical isolates from active duty personnel, resistance
scores were similar regardless of the subject’s deployment-related injury history (P = 0.45).
3.7. ST131 prevalence comparison with 2011 data from USveterans
A recent study determined that among E. coli clinical isolates from 24
VA medical centers across the U.S. E. coli ST131 (predominantly ST131H30) accounted for 7% of ﬂuoroquinolone-susceptible, 78% of
ﬂuoroquinolone-resistant, and 64% of ESBL-producing isolates, and for
28% of E. coli isolates overall (Colpan et al., 2013). Based on the 2% overall
prevalence of ceftriaxone resistance (a proxy for ESBL production) in that
study’s source population (Colpan et al., 2013), back calculations indicated that ST131 accounted for 26% of that study’s non-ESBL producing E. coli
isolates. Thus, the estimated prevalence of ST131 among clinical E. coli isolates in that study versus the present study was 64% versus 32% for ESBLproducing isolates, and 26% versus 24% for non-ESBL-producing isolates.
4. Discussion
In this study we analyzed the clonal background, resistance characteristics, and virulence genotypes of 100 clinical and surveillance E. coli
isolates collected from military personnel and civilians at a US military
medical center. We sought to determine whether distinctive lineages

Table 2
Proportion of Escherichia coli isolates resistant to speciﬁc antimicrobial classes and agents.
Resistance prevalence, no. isolates (%)
ESBLa-producers
Antimicrobial class or agent

b

Any aminoglycoside
Gentamicin
Amikacin
Tobramycin
Any penicillin
Ampicillin
Ampicillin-sulbactam
Piperacillin-tazobactam
Monobactam (aztreonam)
Any cephalosporin
Cefazolin
Cefepime
Cefoxitin
Ceftazidime
Ceftriaxone
Cefuroxime
Any quinolone
Ciproﬂoxacin
Levoﬂoxacin
Nitrofurans (nitrofurantoin)
Tetracyclines (tetracycline)
Anti-folate agents (TMP-SMZ)c
≥3 antibiotic classes (MDR)d
a
b
c
d
e

ESBLa-non-producers

Total
(n = 100)

Clinical
(n = 25)

Surveillance
(n = 25)

Clinical
(n = 25)

Surveillance
(n = 25)

43 (43)
36 (36)
3 (3)
35 (35)
83 (83)
83 (83)
68 (68)
7 (7)
48 (48)
59 (59)
59 (59)
49 (49)
5 (5)
48 (48)
48 (48)
52 (52)
58 (58)
58 (58)
57 (57)
2 (2)
68 (68)
67 (67)
77 (77)

16 (64)
15 (60)
1 (4)
14 (56)
25 (100)
25 (100)
25 (100)
3 (12)
25 (100)
25 (100)
25 (100)
25 (100)
2 (8)
25 (100)
23 (92)
25 (100)
21 (84)
21 (84)
21 (84)
1 (4)
18 (72)
23 (92)
25 (100)

15 (60)
11 (44)
0 (0)
13 (52)
25 (100)
25 (100)
25 (100)
3 (12)
23 (92)
23 (92)
23 (92)
23 (92)
2 (8)
23 (92)
22 (88)
23 (92)
16 (64)
16 (64)
16 (64)
1 (4)
24 (96)
22 (88)
25 (100)

7 (28)
5 (20)
2 (8)
6 (24)
19 (76)
19 (76)
12 (48)
1 (4)
0 (0)
8 (32)
8 (32)
1 (4)
1 (4)
0 (0)
3 (12)
4 (16)
13 (52)
13 (52)
12 (48)
0 (0)
12 (48)
12 (48)
14 (56)

5 (20)
5 (20)
(0)
2 (8)
14 (56)
14 (56)
6 (24)
0 (0)
0 (0)
3 (12)
3 (12)
0 (0)
0 (0)
0 (0)
n.d.e
0 (0)
8 (32)
8 (32)
8 (32)
0 (0)
14 (56)
10 (40)
13 (52)

ESBL, extended-spectrum beta-lactamase.
Antimicrobial classes are listed ﬁrst, followed by the corresponding individual agents that were tested. No resistance was detected to carbapenems (imipenem, meropenem).
TMP-SMZ, trimethoprim-sulfamethoxazole.
MDR, multidrug-resistant.
n.d., not done.
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predominate among such isolates, the degree of similarity between surveillance versus clinical isolates or isolates from active duty personnel
versus civilians, and the comparative prevalence of ST131-H30 in this
population versus among military veterans. The observed clonal distribution largely resembled that expected for North American human
E. coli isolates, with a marked predominance among clinical isolates of
ST131, speciﬁcally its H30 subclone (Salipante et al., 2015). ST10 was
more prevalent among clinical isolates than expected, which could be
due to a greater frequency of cutaneous carriage (Table 1). Associations
of resistance and virulence traits with clonal background and ecological
source followed well-established patterns. Thus, ST131-H30 and ST10
contribute importantly to extraintestinal (especially MDR) E. coli infections among military personnel and associated civilians, possibly justifying special diagnostic and surveillance efforts directed toward them.
Notably, all 4 isolate groups (as deﬁned based on clinical versus surveillance origin and ESBL phenotype) were quite diverse microbiologically, and their predominant STs were familiar contributors to infections
and/or resistance. As such, we found no evidence of an unrecognized
clonal outbreak or endemic focus, especially one involving a novel E. coli
strain. Although the risk of multidrug-resistant E. coli and ExPEC acquisition from international settings clearly is high, and outbreaks stemming
from military deployment are critical to the public health of active duty
military members and civilians (CDC, 2004), our ﬁndings suggest that
“the usual suspects”, led by ST131-H30, are also prevalent in the military
health system. Thus, any future E. coli rapid diagnostics developed for general use should prove useful also within the military.
The third most common clonal group, ST648, is increasingly reported as an emerging MDR pathogen in the literature (Zhang et al., 2016).
In our study, it accounted for all group F study isolates, and was linked to
ESBL production among surveillance isolates. However, it contributed
minimally to the clinical isolate population.
A comparison of the present data with the ﬁndings of Colpan et al.
regarding clinical E. coli isolates from 24 Veterans Affairs medical
centers in 2011 (Colpan et al., 2013) showed that, here, ST131 and
ST131-H30 accounted for only half as great a proportion of ESBLproducing isolates (i.e., 32% versus 64%), but a fairly similar proportion
of non-ESBL-producing or total isolates (26% versus 24%). Further
study would be needed to clarify the basis for these ﬁndings.
Study limitations include the relatively small sample size and the
limited availability of subject data, which restricted the range of epidemiological analyses. Study strengths include the unique study population and the isolates” extensive molecular characterization.
5. Conclusion
We found a predominance of ST131-H30 and ST10 among clinical
and surveillance E. coli isolates from a military medical center. ST131
and H30 were strongly – and uniquely – associated with a clinical origin,
irrespective of ESBL status, supporting special pathogenicity for these
lineages, and in comparison with clinical isolates from US military veterans were similarly common overall, although less common among
ESBL-producing isolates. Resistance traits, virulence genes, and clonal/
phylogenetic groups exhibited familiar associations. Our ﬁndings provide potentially useful insights into the clonal distribution and associated characteristics of E. coli from military personnel and civilians.
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